GTBP

GT Biopharma, Inc. (NASDAQ:GTBP) is a clinical-stage biopharmaceutical company founded in 1965 and headquartered in Brisbane, California. Originally incorporated as OXIS International, Inc., the company underwent a strategic transformation and rebranded to GT Biopharma in July 2017 to focus on developing innovative cancer immunotherapies. The company specializes in immuno-oncology treatments based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein technology platform, with multiple drug candidates currently in clinical and preclinical development stages.